EA201692367A1 - COOL SYRUP CONTAINING AMBROXOL HYDROCHLORIDE - Google Patents

COOL SYRUP CONTAINING AMBROXOL HYDROCHLORIDE

Info

Publication number
EA201692367A1
EA201692367A1 EA201692367A EA201692367A EA201692367A1 EA 201692367 A1 EA201692367 A1 EA 201692367A1 EA 201692367 A EA201692367 A EA 201692367A EA 201692367 A EA201692367 A EA 201692367A EA 201692367 A1 EA201692367 A1 EA 201692367A1
Authority
EA
Eurasian Patent Office
Prior art keywords
ambroxol hydrochloride
syrup containing
containing ambroxol
cool syrup
cool
Prior art date
Application number
EA201692367A
Other languages
Russian (ru)
Other versions
EA036554B1 (en
Inventor
Бернд Пломанн
Катрин Бушелло
Уве Шойринг
Аннетте Зампони
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA201692367A1 publication Critical patent/EA201692367A1/en
Publication of EA036554B1 publication Critical patent/EA036554B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение касается сиропов от кашля, содержащих амброксола гидрохлорид, характеризующихся тем, что они, по существу, не содержат глицерина, и их применения для муколитического лечения острых и хронических заболеваний бронхов и/или легких.The present invention relates to cough syrups containing ambroxol hydrochloride, characterized in that they essentially do not contain glycerol, and their use for mucolytic treatment of acute and chronic diseases of the bronchi and / or lungs.

EA201692367A 2014-05-23 2015-05-19 Cough syrup containing ambroxol hydrochloride EA036554B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14169642 2014-05-23
PCT/EP2015/060991 WO2015177147A1 (en) 2014-05-23 2015-05-19 Cough medicine containing ambroxol hydrochloride

Publications (2)

Publication Number Publication Date
EA201692367A1 true EA201692367A1 (en) 2017-05-31
EA036554B1 EA036554B1 (en) 2020-11-23

Family

ID=50771186

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201692367A EA036554B1 (en) 2014-05-23 2015-05-19 Cough syrup containing ambroxol hydrochloride

Country Status (13)

Country Link
US (1) US20170189330A1 (en)
EP (1) EP3145491B1 (en)
JP (1) JP6554168B2 (en)
KR (1) KR102447263B1 (en)
CN (2) CN106413688A (en)
AU (1) AU2015261940B2 (en)
CA (1) CA2949882C (en)
EA (1) EA036554B1 (en)
ES (1) ES2873078T3 (en)
MX (1) MX2016015303A (en)
PH (1) PH12016502284A1 (en)
PL (1) PL3145491T3 (en)
WO (1) WO2015177147A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018182546A1 (en) 2017-03-27 2018-10-04 İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi Stabilized pharmaceutical syrup composition comprising terbutaline sulphate and ambroxol hydrochloride
CN114129514A (en) * 2021-11-15 2022-03-04 华萃国际生物科技(广东)有限公司 Suspension drop and preparation method and application thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1417961A1 (en) * 2002-11-08 2004-05-12 Boehringer Ingelheim International GmbH New pharmaceutical compositions containing a combination of ambroxol or bromhexine and isopropamide iodide
CN1546008A (en) * 2003-12-02 2004-11-17 沈阳药科大学 Ambroxol hydrochloride liquid sustained release preparation and preparation method thereof
DE102004021992A1 (en) * 2004-05-03 2005-11-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Topical preparation containing ambroxol
WO2006030221A1 (en) * 2004-09-15 2006-03-23 Cipla Limited Pharmaceutical composition comprising a betaminetic agent and a mucolytic agent
JP2008013542A (en) * 2006-06-07 2008-01-24 Daiichi Sankyo Healthcare Co Ltd Pharmaceutical composition for expectoration or inhibiting airway caliciform cell hyperplasia
JP5364330B2 (en) * 2007-10-10 2013-12-11 第一三共ヘルスケア株式会社 Pharmaceutical composition containing azelastine and ambroxol
CN101352417A (en) * 2008-08-29 2009-01-28 扬州市三药制药有限公司 Ambroxol hydrochloride oral solution and preparation method thereof
CN101953821A (en) * 2009-07-15 2011-01-26 北京利乐生制药科技有限公司 Medicinal composition taking levalbuterol and ambroxol as main active ingredients
CN102125540A (en) * 2010-01-18 2011-07-20 沈阳华泰药物研究有限公司 Pharmaceutically acceptable composition containing ambroxol in non-salt form
CN102309442A (en) * 2010-07-07 2012-01-11 澳美制药厂 Ambroxol hydrochloride oral aqueous composition and preparation method thereof
AU2011278451B2 (en) * 2010-07-12 2014-11-27 A. Nattermann & Cie. Gesellschaft mit Beshränkter Haftung Aqueous composition comprising bromhexine
CN102258462A (en) * 2011-07-14 2011-11-30 江西川奇药业有限公司 Method for improving stability of ambroxolhydrochloride
CN102716128A (en) * 2012-07-03 2012-10-10 王学军 Pharmaceutical composition for treating asthma
CN102940616A (en) * 2012-11-21 2013-02-27 北京润德康医药技术有限公司 Ambroxol hydrochloride oral cavity dispersion membrane agent

Also Published As

Publication number Publication date
WO2015177147A1 (en) 2015-11-26
US20170189330A1 (en) 2017-07-06
KR102447263B1 (en) 2022-09-26
EP3145491A1 (en) 2017-03-29
PL3145491T3 (en) 2021-11-02
KR20170010404A (en) 2017-01-31
EA036554B1 (en) 2020-11-23
CN106413688A (en) 2017-02-15
JP2017516849A (en) 2017-06-22
ES2873078T3 (en) 2021-11-03
MX2016015303A (en) 2017-03-06
EP3145491B1 (en) 2021-04-21
CA2949882A1 (en) 2015-11-26
PH12016502284B1 (en) 2017-02-13
AU2015261940A1 (en) 2016-12-08
CN116459204A (en) 2023-07-21
AU2015261940B2 (en) 2020-07-09
CA2949882C (en) 2023-02-28
PH12016502284A1 (en) 2017-02-13
JP6554168B2 (en) 2019-07-31

Similar Documents

Publication Publication Date Title
EA201791029A1 (en) ANTIBODIES AGAINST INTERLEUKIN-33 AND THEIR APPLICATION
KR20180084812A (en) Media content matching and indexing
EA201790398A1 (en) METHODS OF TREATING LIVER DISEASES
EA201692477A1 (en) COMPOSITIONS AND METHODS OF APPLICATION FOR THE TREATMENT OF METABOLIC DISORDERS
EA202090632A1 (en) METHODS AND COMPOSITIONS FOR TREATING DISORDERS WITH THE USE OF FALLISTATIN POLYPEPTIDES
IL261721A (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors
EA201691594A1 (en) CYCLOPROPYLAMINES AS LSD1 INHIBITORS
BR112017008659A2 (en) ? gip agonist methods and compounds?
EA201790273A1 (en) FLAGELLIN COMPOSITIONS AND THEIR APPLICATION
MX2017000307A (en) Treatment of leukemia with histone deacetylase inhibitors.
EA201691610A8 (en) ANTI-JAGGED1 ANTIBODIES AND METHODS OF APPLICATION
CR20170219A (en) BROMODOMINUM INHIBITORS
BR112018001853A2 (en) methods for treating a disorder and for improving the treatment of a disorder
EA201890810A1 (en) COMPOUNDS EFFECTIVE FOR THE TREATMENT OF HEPATOTOXICITY AND LIVER STEATOSIS AND THEIR APPLICATION
BR112016017112A2 (en) APILIMOD COMPOSITIONS AND METHODS OF USE THEREOF
TR201901348T4 (en) Pyrrolidinone derivatives as metap-2 inhibitors.
EA201790787A1 (en) REDUCTION OF VISCOSITY OF PHARMACEUTICAL COMPOSITIONS
DK3442513T3 (en) USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED DISORDERS
CL2019000872A1 (en) Sweetener composition with a better taste quality comprising allulose and salt, and the method to improve the quality of taste of the allulose using salt.
EA201892287A1 (en) PHARMACEUTICAL COMBINATIONS FOR CANCER TREATMENT
AR100944A1 (en) INTERFERON ANTAGONIST ANTIBODIES a Y w
UY36173A (en) METHOD OF TREATMENT OF DISEASES RELATED TO THE INDICATABLE FACTOR FOR HYPOXIA
EA201692367A1 (en) COOL SYRUP CONTAINING AMBROXOL HYDROCHLORIDE
BR112017021413A2 (en) anti-flt-1 antibodies in the treatment of bronchopulmonary dysplasia.
BR112017019373A2 (en) computer-implemented method and computer-readable media

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG TJ TM